Live tape
Top 8, mentions 7d6,310NVDA1,035 mentions▲ +0.09NKE1,015 mentions+0.01GOOGL992 mentions▲ +0.04LULU957 mentions▲ +0.03TSLA869 mentions▲ +0.06META502 mentions▲ +0.04VOO471 mentions▲ +0.08QQQ469 mentions▲ +0.08

Equity · Healthcare

CYTK

Cytokinetics, Incorporated · NasdaqGS

$81 −1.22% 1D Finazon · prior-day close · Jul 24, 2026
Price · Chart
Our own end-of-day closes 30 sessions
$90 $60 11 Jun 24 Jul

The line runs $69.27 on 11 June through $81 on 24 July, on a scale from $60 to $90. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of CYTK over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 30 sessions over that window: $69.27 on 11 June 2026 through $81 on 24 July 2026.

Market cap $11.3B
52-week range $33.20 – $87.31
Avg volume 477.5K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 9, 2026

CYTK insider trades

SEC Form 4 · last 90 days · newest reported trade 8 Sep 2026
Open-market buys 0
Open-market sells 18
Net sold $11.90M
Non-trade filings 21
Date Insider Type Shares Value
08 Sep 2026 Malik Fady Ibraham EVP Research & Development Sell 3,500 $264K
01 Sep 2026 PARSHALL B LYNNE Director Sell 5,000 $357K
31 Aug 2026 Blum Robert I President & CEO Sell 7,500 $527K
31 Aug 2026 Callos Andrew EVP, Chief Commercial Officer Sell 10,000 $702K
18 Aug 2026 Malik Fady Ibraham EVP Research & Development Sell 3,500 $265K
10 Aug 2026 Blum Robert I President & CEO Sell 7,500 $576K
30 Jul 2026 Callos Andrew EVP, Chief Commercial Officer Sell 14,000 $1.12M
27 Jul 2026 Blum Robert I President & CEO Sell 7,500 $607K
21 Jul 2026 Malik Fady Ibraham EVP Research & Development Sell 3,500 $282K
13 Jul 2026 Blum Robert I President & CEO Sell 7,500 $615K
07 Jul 2026 Malik Fady Ibraham EVP Research & Development Sell 3,500 $303K
01 Jul 2026 Blum Robert I President & CEO Sell 7,500 $637K

Showing the 12 most recent of 18 open-market trades in this window. The figures above count all of them.

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
08 Sep 2026 Malik Fady Ibraham EVP Research & Development Option exercise 3,500 $27K
31 Aug 2026 Blum Robert I President & CEO Option exercise 7,500 $80K
31 Aug 2026 Callos Andrew EVP, Chief Commercial Officer Option exercise 10,000 $233K
18 Aug 2026 Malik Fady Ibraham EVP Research & Development Option exercise 3,500 $27K
10 Aug 2026 Blum Robert I President & CEO Option exercise 7,500 $80K
30 Jul 2026 Callos Andrew EVP, Chief Commercial Officer Option exercise 14,000 $326K
27 Jul 2026 Blum Robert I President & CEO Option exercise 7,500 $80K
21 Jul 2026 Malik Fady Ibraham EVP Research & Development Option exercise 3,500 $27K
15 Jul 2026 Daly James M Director Award 151 $12K
15 Jul 2026 Harrington Robert Arthur Director Award 151 $12K
15 Jul 2026 HENDERSON JOHN T Director Award 272 $22K
15 Jul 2026 Kaye Edward M. MD Director Award 151 $12K

Showing the 12 most recent of 21 compensation filings in this window. The figures above count all of them.

CYTK reported financials

SEC EDGAR XBRL

CYTK reported revenue of $88.0M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$785.0M.

Figure Reported Period
Revenue $88.0M 31 Dec 2025 fiscal year
Net income −$785.0M 31 Dec 2025 fiscal year
Diluted EPS −$6.54 31 Dec 2025 fiscal year
Total assets $1.9B 30 Jun 2026 at period end
Total equity −$173.5M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

CYTK earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-1.50 —
31 Mar 2026 Q1 2026 $-1.67 —
31 Dec 2025 FY 2025 $-6.54 —
30 Sep 2025 Q3 2025 $-2.55 —
30 Jun 2025 Q2 2025 $-1.12 —
31 Mar 2025 Q1 2025 $-1.36 —
31 Dec 2024 FY 2024 $-5.26 —
30 Sep 2024 Q3 2024 $-1.36 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

CYTK institutional holders

SEC Form 13F

12 of the 45 institutional funds we track reported a CYTK position for the quarter ended 30 Jun 2026 — a combined $519.1M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Point72 Asset Management Added +153.6% shares 1,587,712 $135.3M
D. E. Shaw & Co. Added +48.3% shares 1,048,103 $89.3M
Fisher Asset Management Held (±25%) −3.2% shares 743,697 $63.4M
Balyasny Asset Management Trimmed −28.3% shares 711,676 $60.6M
Citadel Advisors Trimmed −41.7% shares 640,945 $54.6M
Marshall Wace Trimmed −31.2% shares 451,467 $38.5M
Two Sigma Investments Held (±25%) +11.4% shares 317,411 $27.0M
Baker Bros. Advisors New position 211,267 $18.0M
AQR Capital Management Held (±25%) +3.4% shares 161,903 $13.8M
Millennium Management Held (±25%) +12.0% shares 109,717 $9.3M

Showing the 10 largest of 12 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

CYTK fails-to-deliver

SEC CNS data

On 12 Aug 2026, 10,465 shares of CYTK failed to deliver (about $800K) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
12 Aug 2026 10,465 $800K 0.008%
11 Aug 2026 1,196 $93K 0.001%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in CYTK

STOCK Act disclosures

The most recent congressional trade disclosed in CYTK is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 30 Jun 2026.

Date Member Type Amount
30 Jun 2026 filed 02 Jul 2026 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K

Source: U.S. House of Representatives financial disclosures